HCV New Drugs

This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.

Risk Of Developing Liver Cancer After HCV Treatment

▼

Showing posts with label AL-335. Show all posts

Showing posts with label AL-335. Show all posts

Monday, September 11, 2017

Janssen to Discontinue Hepatitis C Development Program

J&J pulls plug on Medivir-Achillion hep C cocktail to focus on hep B by Ben Adams Why? The same r...

Monday, November 28, 2016

Janssen has initiated phase IIb study of simeprevir, odalasvir and AL-335

Medivir announces that Janssen has initiated an open-label phase IIb study of the 3DAA combination of simeprevir, odalasvir and AL-335 (JNJ-...

Wednesday, May 11, 2016

Janssen to Start a Phase IIb Study/Combinations of Simeprevir, Odalasvir and AL-335 for the Treatment of Hepatitis C

Study identifier: NCT02765490. Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) or AL-335 and ODV in the...

Friday, October 16, 2015

Janssen Initiates Phase 2a HCV Study: AL-335, Odalasvir (ACH-3102), and Simeprevir for Genotype 1

Achillion Announces That Janssen Has Initiated a Phase 2a Study to Evaluate the Combination of AL-335, Odalasvir (ACH-3102), and Simeprevir ...

View web version

Powered by Blogger.